Abstract
Adoptive immunotherapy with lymphokine-activated killer (LAK) cells is an interesting new therapeutic approach in cancer treatment in which autologous cells with antitumoral activity have been induced with interleukin-2 (IL-2) in vivo and/or in vitro and retransfused to tumor-bearing animals or cancer patients [6, 10, 11]. LAK cells have been shown to be different from natural killer/ killer (NK/K) cells and cytotoxic T cells (CTL) and can lyse autologous and allogeneic, immunogenic and nonimmunogenic neoplasms or malignant cell lines, including NK-resistant tumor cells. The origin of LAK cells is still a subject of controversy, and there is discussion as to whether the LAK precursor and/or mature LAK cells are non-T or T cells or similar to the NK/K population [2, 4, 17].
This work was supported by the Cilli-Weill Stiftung, the Riese Stiftung and Edith v. Heyden Vermächtnis, and the Paul and Ursula Klein Stiftung.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bergmann L, Mitrou PS, Demmer-Dieckmann M, Ruhmann FT, Weidmann E (1987) impaired t- and b-cell functions in patients with hodgkin’s disease. Reduced mitogenic responsibility and il-2 production is not caused by defective cd4+-cells. Cancer immunol immunother 25: 59–64
Bergmann L, Mitrou PS, Schmidt-Matthiesen A, Lautenschläger G, Griesinger F, Encke A, Hoelzer D (1987) Lymphocyte subsets and LAK-cell induction in patients with gastric cancer by in vitro and in vivo application of recombinant human interleukin-2. Blut 55: 257
Bol SJ, Rosdorff HJ, Ronteltap CP, Hennen LA (1986) Cellular cytotoxicity assessed by the 51Cr-release assay. J Immunol Methods 90: 15 - 23
Grimm EA (1986) Human lymphokine-activated killer cells (LAK cells) as a potential im-munotherapeutic modality. Biochim Biophys Acta 865: 267 - 279
Itoh K, Shibia K, Shimizu Y, Suzuki R, Kumagi K (1985) Generation of activated killer (AK) cells by recombinant interleukin-2 (rIL-2) in collaboration with interferon-γ ( IFN-γ ). J Immunol 134: 3124–3129
Lafreniere R, Rosenberg SA (1985) Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK cells and recombinant interleukin-2 (rIL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J Immunol 135: 4273–4280
Lotze MT, Matory YL, Rayner A A, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg S A (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 2764 - 2772
Nishimura T, Togashi Y, Goto M, Yagi H, Uchiyama Y, Hashimoto Y (1986) Augmentation of the therapeutic efficiency of adoptive immunotherapy by in vitro administration of slowly released recombinant interleukin-2. Cancer Immunol Immunother 21: 12–18
Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH (1987) Long-term growth of lympho-kine-activated killer (LAK) cells: role of anti-CD3, ß-IL–1, interferon-γ and-ß. J Immunol 138: 2728 - 2733
Rosenberg SA (1985) A new approach to the treatment of cancer using the adoptive transfer of lymphokine activated killer cells and recombinant interleukin-2. Cancer Res 45: 131–149
Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach of the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson CG, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastic cancer. N Engl J Med 313: 1485–1492
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897
Salup RR, Wiltrout RH (1986) Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2 stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease. Cancer Immunol Immunother 22: 31–36
Shiba K, Suzuki R, Kawakami K, Ohuchi A, Kumagai K (1986) Interleukin-2 activated killer cells: generation in collaboration with interferon-γ and its suppression in cancer patients. Cancer Immunol Immunother 21: 119–128
Shu S, Rosenberg SA (1985) Adoptive immunotherapy of a newly induced sarcoma. J Immunol 135: 2895 - 2903
Truitt RL, Gale RP, Boitin MM (1987) Cellular immunotherapy of cancer. Prog Clin Biol Res, Vol 244, A.L. Riss Inc., New York
Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA (1987) Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5: 496–503
West WH, Tauer KW, Yanelle JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bergmann, L., Mitrou, P.S., Weidmann, E., Schmidt-Matthiesen, A., Hanke, P., Hoelzer, D. (1989). In Vitro and In Vivo Induction of Lymphokine-Activated Killer Cells in Patients with Gastric Cancer and Other Solid Tumors. In: Koldovsky, P., Koldovsky, U., Beck, L., Vosteen, KH. (eds) Lymphocytes in Immunotherapy of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74225-5_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-74225-5_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50457-3
Online ISBN: 978-3-642-74225-5
eBook Packages: Springer Book Archive